NON-BIG CAP BIOTECH PROFIT UP 42.5%, REVENUE UP 9.5%
September 5th 2010 21:53
Biotech Daily
Wednesday September 1, 2010
Daily news on ASX-listed biotechnology companies
Wednesday September 1, 2010
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH PROFIT, REVENUE 2009-‘10
Non-Big Cap revenue for the year to June 30, 2010 was up 9.5 percent to $508.33 million, with profit up 42.5 percent to $97.2 million compared to the previous year.
CSL’s eight percent fall in revenue and profit reduced total biotech profit 0.4 percent to $1512.8 million on total revenue down 2.9 percent to $7,079.1 million. Gains by Resmed and Cochlear were not enough to compensate for CSL’s fall.
The non Big Cap gains primarily came from Acrux, Biota, Cellestis, Probiotec and Sirtex, with Halcygen and Nusep posting maiden profits and Probiomics seeing a turnaround profit.
Imugene and Resonance posted maiden profits for 2008-’09 but saw a fall in revenue and profits turned to losses.
The companies covered only include those with sales of product and do not include the vast majority of biotechnology companies with minimal revenues from grants or loans and have ongoing losses.
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 57 |
| Vote |
Add To: 
subscribe to this blog